Immune Cell Function Assay
Customize your policy alerts
Sign up for Blue Cross Blue Shield - Oklahoma Policy CPCPLAB028 alerts
Get alerted when Policy CPCPLAB028 changes without checking for updates manually.
Monitor payer policy activity
Defines reimbursement and coding guidance for immune cell function assays, primarily in the context of monitoring/predicting immune function after solid organ transplantation; applicable to providers submitting claims to BCBSOK.
No material clinical or coverage changes in this revision.
Coverage Criteria
Reimbursable Indication
Covered when used to monitor and predict immune function after solid organ transplantation.
Coverage may depend on member plan documents and provider contract.
Not Reimbursable / Excluded Indications
Not reimbursable for the following indications (examples include but are not limited to):
List is not exhaustive.
The policy permits reimbursement for an immune cell function assay when it is used to monitor and predict immune function after solid organ transplantation. Coverage is limited to this transplant-related context and may depend on member plan documents and provider contracts. Providers should ensure submitted claims and documentation clearly indicate the post–solid organ transplant indication to support payment.
This policy identifies several scenarios where immune cell function assays are not reimbursable. Examples include management of autologous or allogeneic hematopoietic stem cell transplantation; management of immunodeficiency disorders including HIV and SCID; management or prediction of infection risk in immune-mediated disorders such as rheumatoid arthritis, multiple sclerosis, and lupus nephritis; testing for urticaria; diagnosis and management of Lyme disease (for example, iSpot Lyme Test); management of inflammatory bowel diseases; and monitoring immune response following surgery. This list is not exhaustive; claims submitted for these indications are subject to denial.
Coding
Provider Actions and Billing Guidance
Plan-specific prior authorization
Plan-specific prior authorization requirements may apply to certain products. Providers should review the member's plan documents and benefit coverage to determine whether prior authorization or other product-specific requirements are needed before performing or billing for testing.
- Not all laboratory management reimbursement criteria apply to every product; check plan documents for eligible coverage.
Documentation expectations
Providers are responsible for submission of accurate and complete documentation supporting the medical necessity and coding of services billed. Upon request, providers must submit additional documentation to support the claim, including clinical records, test reports, and rationale for the test ordered.
- Submit claims using valid HIPAA-approved code sets (CPT, HCPCS, ICD-10, NDC, etc.).
- Be prepared to provide additional documentation upon request to support medical necessity and correct coding.
Denial triggers and coding expectations
Claims may be denied if submitted for non-reimbursable indications or if coding does not conform to industry-standard guidelines and plan/contract terms. Providers should code services according to standard coding guidance and ensure the billed indication is a covered reason per plan documents.
- Immune cell function assays may be reimbursable for monitoring/predicting immune function after solid organ transplantation; verify coverage for the specific product and member.
- Immune cell function assays are not reimbursable for certain indications including management of hematopoietic stem cell transplantation, immunodeficiency disorders (e.g., HIV, SCID), prediction of infection risk in immune-mediated disorders (e.g., RA, MS, lupus nephritis), testing for urticaria, diagnosis/management of Lyme disease (e.g., iSpot Lyme Test), management of inflammatory bowel diseases, or monitoring immune response following surgery.
- Claims are subject to code edit protocols, claim review, provider contract language, medical policies, clinical payment and coding policies, and coding software logic.
Definitions
Background
Immune cell function assays are cell‑based laboratory tests that assess cell‑mediated immune response, for example measuring CD4+ T‑cell activity, and are applied primarily to evaluate risk of infection or rejection in transplant populations. The clinical evidence cited in the policy evaluates assays such as ImmuKnow and other CD4+ T‑cell function tests across solid organ transplant types; however, routine use outside the post‑transplant monitoring context is not supported by this coverage policy.
Transplant-Related Coverage Note
Transplant-related coverage note
Assay use relevant to transplant populations.
Clinical references cited in the policy address kidney, liver, heart, lung and pediatric transplant literature.
Evaluation Requirements
Review plan documents for product‑specific evaluation and lab management rules
The policy does not list specific pre‑approval evaluation or lab management steps; providers should consult plan documents and member-specific coverage rules for any required pre‑authorization, lab routing, or management protocols.
- Because not all lab management reimbursement criteria apply to every product, verify product‑specific rules in the member’s plan documents before ordering.
- Supply any requested documentation and follow plan or contract directions for lab provider networks or specimen handling if specified.
Post-Transplant Coverage
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.